Oramed Pharmaceuticals (XTAE:ORMP) Total Assets : ₪745.21 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Oramed Pharmaceuticals Total Assets?

Oramed Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was ₪745.21 Mil.

During the past 12 months, Oramed Pharmaceuticals's average Total Assets Growth Rate was 347.50% per year. During the past 3 years, the average Total Assets Growth Rate was 131.20% per year. During the past 5 years, the average Total Assets Growth Rate was 36.50% per year. During the past 10 years, the average Total Assets Growth Rate was 42.10% per year.

During the past 13 years, Oramed Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 700.00%. The lowest was -41.40%. And the median was 35.50%.

Total Assets is connected with ROA %. Oramed Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 was 2.90%. Total Assets is also linked to Revenue through Asset Turnover. Oramed Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Oramed Pharmaceuticals Total Assets Historical Data

The historical data trend for Oramed Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Total Assets Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

126.84

163.32

468.38

591.49

807.05

Oramed Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															584.67	571.99	844.89	807.05	745.21

Oramed Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Oramed Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	596.066	+	210.985
	=	807.05

Oramed Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	606.414	+	138.799
	=	745.21

Oramed Pharmaceuticals (XTAE:ORMP) Total Assets Explanation

Total Assets is connected with ROA %.

Oramed Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	22.484	/	( (807.05	+	745.213)	/ 2 )
	=	22.484	/	776.1315
	=	2.90 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Oramed Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (807.05	+	745.213)	/ 2 )
=	0	/	776.1315
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Oramed Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (XTAE:ORMP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (XTAE:ORMP) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

ORMP:USA OJU1:Germany

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.